Shares of Astellas Pharma Inc. (OTCMKTS:ALPMY – Get Free Report) passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $10.77 and traded as low as $9.64. Astellas Pharma shares last traded at $9.71, with a volume of 89,294 shares.
Astellas Pharma Stock Performance
The company has a debt-to-equity ratio of 0.39, a quick ratio of 0.80 and a current ratio of 1.04. The stock’s fifty day moving average is $9.62 and its two-hundred day moving average is $10.76. The firm has a market cap of $17.57 billion, a price-to-earnings ratio of -44.13 and a beta of 0.34.
Astellas Pharma (OTCMKTS:ALPMY – Get Free Report) last announced its earnings results on Tuesday, February 4th. The company reported $0.30 earnings per share (EPS) for the quarter. Astellas Pharma had a negative net margin of 3.10% and a positive return on equity of 13.69%. On average, analysts expect that Astellas Pharma Inc. will post 0.42 earnings per share for the current fiscal year.
About Astellas Pharma
Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.
See Also
- Five stocks we like better than Astellas Pharma
- How to Calculate Options Profits
- Chaos and Cash: Finding Opportunity in Volatility
- How to Use the MarketBeat Excel Dividend Calculator
- Realty Income: An Anchor in Volatile Markets
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Autodesk Designs Value for Investors: Uptrend Set to Continue
Receive News & Ratings for Astellas Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astellas Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
